000143815 001__ 143815
000143815 005__ 20240229112609.0
000143815 0247_ $$2doi$$a10.1002/ijc.32312
000143815 0247_ $$2pmid$$apmid:30945750
000143815 0247_ $$2ISSN$$a0020-7136
000143815 0247_ $$2ISSN$$a1097-0215
000143815 0247_ $$2altmetric$$aaltmetric:59057949
000143815 037__ $$aDKFZ-2019-01377
000143815 041__ $$aeng
000143815 082__ $$a610
000143815 1001_ $$aKyuno, Daisuke$$b0
000143815 245__ $$aClaudin7-dependent exosome-promoted reprogramming of nonmetastasizing tumor cells.
000143815 260__ $$aBognor Regis$$bWiley-Liss$$c2019
000143815 3367_ $$2DRIVER$$aarticle
000143815 3367_ $$2DataCite$$aOutput Types/Journal article
000143815 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1567670221_28320
000143815 3367_ $$2BibTeX$$aARTICLE
000143815 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143815 3367_ $$00$$2EndNote$$aJournal Article
000143815 520__ $$aClaudin7 (cld7) is a cancer-initiating cell (CIC) marker in gastrointestinal tumors, a cld7-knockdown (kd) being accompanied by loss of tumor progression. Tumor exosomes (TEX) restoring CIC activities, we explored the contribution of cld7. This became particularly interesting, as tight junction (TJ)- and glycolipid-enriched membrane domain (GEM)-derived cld7 is recruited into distinct TEX. TEXs were derived from CIC or cld7kd cells of a rat pancreatic and a human colon cancer line. TEX derived from pancreatic cancer cld7kd cells rescued with palmitoylation site-deficient cld7 (cld7mP) allowed selectively evaluating the contribution of GEM-derived TEX, only palmitoylated cld7 being integrated into GEM. Cld7 CIC-TEX promoted tumor cell dissemination and metastatic growth without a major impact on proliferation, apoptosis resistance and epithelial-mesenchymal transition. Instead, migration, invasion and (lymph)angiogenesis were strongly supported, only migration being selectively fostered by GEM-derived cld7 TEX. CIC-TEX coculture of cld7kd cells uncovered significant changes in the cld7kd cell protein and miRNA profiles. However, changes did not correspond to the CIC-TEX profile, CIC-TEX rather initiating integrin, protease and RTK, particularly lymphangiogenic receptor activation. CIC-TEX preferentially rescuing cld7kd-associated defects in signal transduction was backed up by an RTK inhibitor neutralizing the impact of CIC-TEX on tumor progression. In conclusion, cld7 contributes to selective steps of the metastatic cascade. Defects of cld7kd and cld7mP cells in migration, invasion and (lymph)angiogenesis are effaced by CIC-TEX that act by signaling cascade activation. Accordingly, RTK inhibitors are an efficient therapeutic defeating CIC-TEX.
000143815 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143815 588__ $$aDataset connected to CrossRef, PubMed,
000143815 7001_ $$aZhao, Kun$$b1
000143815 7001_ $$0P:(DE-He78)38b33779833838a98c2a241ce465fb07$$aSchnölzer, Martina$$b2$$udkfz
000143815 7001_ $$aProvaznik, Jan$$b3
000143815 7001_ $$aHackert, Thilo$$b4
000143815 7001_ $$aZöller, Margot$$b5
000143815 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32312$$gp. ijc.32312$$n8$$p2182-2200$$tInternational journal of cancer$$v145$$x1097-0215$$y2019
000143815 909CO $$ooai:inrepo02.dkfz.de:143815$$pVDB
000143815 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38b33779833838a98c2a241ce465fb07$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143815 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143815 9141_ $$y2019
000143815 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143815 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143815 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143815 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143815 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000143815 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143815 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143815 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143815 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143815 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143815 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143815 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000143815 9201_ $$0I:(DE-He78)B100-20160331$$kB100$$lFunktionelle Proteomanalyse$$x0
000143815 980__ $$ajournal
000143815 980__ $$aVDB
000143815 980__ $$aI:(DE-He78)B100-20160331
000143815 980__ $$aUNRESTRICTED